AR096246A1 - Derivados de benzimidazol como inhibidores de bromodominio - Google Patents
Derivados de benzimidazol como inhibidores de bromodominioInfo
- Publication number
- AR096246A1 AR096246A1 ARP140101893A ARP140101893A AR096246A1 AR 096246 A1 AR096246 A1 AR 096246A1 AR P140101893 A ARP140101893 A AR P140101893A AR P140101893 A ARP140101893 A AR P140101893A AR 096246 A1 AR096246 A1 AR 096246A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- groups
- optionally substituted
- heteroarylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) donde R¹ᵃ y R¹ᵇ son en forma independiente entre sí alquilo C₁₋₆ opcionalmente sustituido con entre 1 y 5 grupos R²⁰; R²ᵃ y R²ᵇ son en forma independiente entre sí H o halo; R³ es ácido borónico o halo; o -C(O)ORᵃ, -NHC(O)ORᵃ, -NHS(O)₂Rᵃ, o -S(O)₂NRᵃRᵇ; o se selecciona entre el grupo que consiste en alquilo C₁₋₁₀, alcoxi C₁₋₁₀, amino, arilo C₅₋₁₀, arilalquilo C₆₋₂₀, heteroalquilo C₁₋₁₀, heteroarilo C₅₋₁₀, y heteroarilalquilo C₆₋₁₀, cada uno de los cuales está opcionalmente sustituido con entre 1 y 5 grupos R²⁰; uno de R⁴ᵃ y R⁴ᵇ se selecciona entre el grupo que consiste en H y alquilo C₁₋₆ opcionalmente sustituido con entre 1 y 5 grupos R²⁰, y el otro se encuentra ausente; R⁵ es -C(O)ORᵃ, -NHC(O)ORᵃ, -NHS(O)₂Rᵃ, o -S(O)₂NRᵃRᵇ; o se selecciona entre el grupo que consiste en H, alquilo C₁₋₁₀, haloalquilo C₁₋₁₀, alcoxi C₁₋₁₀, amino, arilo C₅₋₁₀, arilalquilo C₆₋₂₀, heteroalquilo C₁₋₁₀, heteroarilo C₅₋₁₀, y heteroarilalquilo C₆₋₂₀, cada uno de los cuales está opcionalmente sustituido con entre 1 y 5 grupos R²⁰; cada Rᵃ y Rᵇ se selecciona en forma independiente entre el grupo que consiste en H, alquilo C₁₋₁₀, arilo C₅₋₁₀, arilalquilo C₆₋₂₀, heteroalquilo C₁₋₁₀, heteroarilo C₁₋₁₀, y heteroarilalquilo C₆₋₂₀, cada uno de los cuales está opcionalmente sustituido con entre 1 y 5 grupos R²⁰; y cada R²⁰ se selecciona en forma independiente entre el grupo que consiste en acilo, alquilo C₁₋₁₀, alcoxi C₁₋₁₀, amino, amido, amidino, arilo C₅₋₁₀, arilalquilo C₆₋₂₀, azido, carbamoilo, carboxilo, éster de carboxilo, ciano, guanidino, halo, haloalquilo C₁₋₁₀, heteroalquilo C₁₋₁₀, heteroarilo C₅₋₁₀, heteroarilalquilo C₆₋₂₀, hidroxi, hidrazino, hidroxilo, imino, oxo, nitro, sulfinilo, ácido sulfónico, sulfonilo, tiocianato, tiol, y tiona; donde los grupos alquilo C₁₋₁₀, arilo C₅₋₁₀, arilalquilo C₆₋₂₀, heteroalquilo C₁₋₁₀, heteroarilo C₅₋₁₀, y heteroarilalquilo C₆₋₂₀ están opcionalmente sustituidos con entre 1 y 3 sustituyentes seleccionados en forma independiente entre alquilo C₁₋₆, arilo C₅₋₁₀, halo, haloalquilo C₁₋₆, ciano, hidroxilo, y alcoxi C₁₋₆; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361821612P | 2013-05-09 | 2013-05-09 | |
| US201361826912P | 2013-05-23 | 2013-05-23 | |
| US201361860229P | 2013-07-30 | 2013-07-30 | |
| US201461951347P | 2014-03-11 | 2014-03-11 | |
| PCT/US2014/037344 WO2014182929A1 (en) | 2013-05-09 | 2014-05-08 | Benzimidazole derivatives as bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096246A1 true AR096246A1 (es) | 2015-12-16 |
Family
ID=50897952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101893A AR096246A1 (es) | 2013-05-09 | 2014-05-09 | Derivados de benzimidazol como inhibidores de bromodominio |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9458145B2 (es) |
| EP (1) | EP2994469B1 (es) |
| JP (1) | JP6049942B2 (es) |
| KR (1) | KR101761049B1 (es) |
| CN (1) | CN105324379B (es) |
| AP (1) | AP2015008869A0 (es) |
| AR (1) | AR096246A1 (es) |
| AU (1) | AU2014262622B2 (es) |
| BR (1) | BR112015028017A2 (es) |
| CA (1) | CA2911408C (es) |
| CL (1) | CL2015003280A1 (es) |
| CR (1) | CR20150639A (es) |
| EA (1) | EA029091B1 (es) |
| ES (1) | ES2710120T3 (es) |
| HK (2) | HK1219278A1 (es) |
| MD (1) | MD4592B1 (es) |
| MX (1) | MX2015015478A (es) |
| NZ (1) | NZ713718A (es) |
| PE (1) | PE20160029A1 (es) |
| PH (1) | PH12015502534A1 (es) |
| PT (1) | PT2994469T (es) |
| SG (1) | SG11201509220XA (es) |
| TW (1) | TWI527811B (es) |
| UA (1) | UA112618C2 (es) |
| UY (1) | UY35559A (es) |
| WO (1) | WO2014182929A1 (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| EP3581576B1 (en) | 2013-03-15 | 2022-01-26 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor |
| ES2806135T3 (es) | 2013-06-21 | 2021-02-16 | Zenith Epigenetics Ltd | Nuevos inhibidores de bromodominios bicíclicos |
| ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
| US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| TWI735002B (zh) | 2014-04-23 | 2021-08-01 | 美商英塞特公司 | 作為BET蛋白抑制劑之1H-吡咯并[2,3-c]吡啶-7(6H)-酮及吡唑并[3,4-c]吡啶-7(6H)-酮 |
| CN107108552A (zh) * | 2014-08-05 | 2017-08-29 | 百时美施贵宝公司 | 杂环激酶抑制剂 |
| ES2855225T3 (es) * | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) * | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| CA2966452A1 (en) * | 2014-12-17 | 2016-06-23 | Samuel David Brown | Substituted bicyclic compounds as bromodomain inhibitors |
| GB201504689D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN104788441A (zh) * | 2015-04-02 | 2015-07-22 | 湖南华腾制药有限公司 | 一种多取代苯并恶唑衍生物的制备方法 |
| GB201506658D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| KR20180004811A (ko) * | 2015-05-15 | 2018-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서의 활성을 갖는 벤즈이미다졸 및 이미다조피리딘 카르복스이미드아미드 화합물 |
| US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
| BR112018005497A2 (pt) | 2015-09-21 | 2018-10-09 | Plexxikon Inc | compostos heterocíclicos e usos dos mesmos |
| AU2016329075A1 (en) * | 2015-10-02 | 2018-04-26 | Gilead Sciences, Inc. | Combinations of the BTK inhibitor GS-4059 with inhibitors selected from a JAK, ASK1, BRD and/or MMP9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| CN108689945A (zh) * | 2015-12-01 | 2018-10-23 | 江苏理工学院 | 一种苯并咪唑衍生物的制备方法 |
| CU20180059A7 (es) | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| BR112018013063A2 (pt) * | 2015-12-24 | 2018-12-11 | Celgene Quanticel Res Inc | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal |
| TWI786050B (zh) | 2016-06-20 | 2022-12-11 | 美商英塞特公司 | Ｂｅｔ抑制劑之結晶固體形式 |
| IL263917B (en) | 2016-06-24 | 2022-07-01 | Univ California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| HUE058289T2 (hu) * | 2016-10-27 | 2022-07-28 | Celgene Quanticel Res Inc | Brómdomén és extraterminális protein inhibitor kombinációs terápia |
| US20180133212A1 (en) * | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| US20180179191A1 (en) | 2016-11-22 | 2018-06-28 | Gilead Sciences, Inc. | Synthesis of a compound that modulates the activity of bromodomain-containing proteins |
| US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| WO2018106433A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| US20180153868A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| EP4190318A1 (en) * | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| CN108314680A (zh) * | 2017-01-16 | 2018-07-24 | 凯惠科技发展(上海)有限公司 | 一种含芳环化合物、其制备方法、药物组合物及应用 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US11493520B2 (en) * | 2017-05-19 | 2022-11-08 | Epicypher, Inc. | Assays for nucleosome remodeling activity |
| TWI795440B (zh) | 2017-09-15 | 2023-03-11 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物 |
| WO2019120234A2 (zh) | 2017-12-20 | 2019-06-27 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
| IL300572A (en) | 2018-02-13 | 2023-04-01 | Gilead Sciences Inc | PD–1/PD–L1 inhibitors |
| GB201806320D0 (en) * | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| US11497549B2 (en) * | 2018-05-08 | 2022-11-15 | Boston Scientific Medical Device Limited | Methods and devices for puncturing tissue |
| CN117304130A (zh) | 2018-05-14 | 2023-12-29 | 吉利德科学公司 | Mcl-1抑制剂 |
| CA3105099A1 (en) | 2018-06-29 | 2020-01-02 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (cbp) |
| JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN109912584B (zh) * | 2019-03-22 | 2021-08-13 | 中国药科大学 | 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用 |
| CN113544129B (zh) * | 2019-04-04 | 2024-07-23 | 上海华汇拓医药科技有限公司 | 三环类化合物制备方法及其在医药领域的应用 |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2008109943A1 (en) | 2007-03-12 | 2008-09-18 | Cytopia Research Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| MX2010001650A (es) | 2007-08-10 | 2010-08-02 | Glaxosmithkline Llc | Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales. |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| EP3009427B1 (en) | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| GB201106799D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| US9193717B2 (en) * | 2011-10-13 | 2015-11-24 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
-
2014
- 2014-05-07 TW TW103116235A patent/TWI527811B/zh active
- 2014-05-08 CN CN201480035623.0A patent/CN105324379B/zh active Active
- 2014-05-08 EA EA201591965A patent/EA029091B1/ru not_active IP Right Cessation
- 2014-05-08 EP EP14729182.7A patent/EP2994469B1/en active Active
- 2014-05-08 ES ES14729182T patent/ES2710120T3/es active Active
- 2014-05-08 AP AP2015008869A patent/AP2015008869A0/xx unknown
- 2014-05-08 NZ NZ713718A patent/NZ713718A/en not_active IP Right Cessation
- 2014-05-08 PE PE2015002375A patent/PE20160029A1/es not_active Application Discontinuation
- 2014-05-08 US US14/273,147 patent/US9458145B2/en active Active
- 2014-05-08 CA CA2911408A patent/CA2911408C/en active Active
- 2014-05-08 SG SG11201509220XA patent/SG11201509220XA/en unknown
- 2014-05-08 AU AU2014262622A patent/AU2014262622B2/en active Active
- 2014-05-08 JP JP2016513078A patent/JP6049942B2/ja active Active
- 2014-05-08 WO PCT/US2014/037344 patent/WO2014182929A1/en active Application Filing
- 2014-05-08 US US14/787,374 patent/US20160075695A1/en not_active Abandoned
- 2014-05-08 MX MX2015015478A patent/MX2015015478A/es unknown
- 2014-05-08 MD MDA20150121A patent/MD4592B1/ro not_active IP Right Cessation
- 2014-05-08 PT PT14729182T patent/PT2994469T/pt unknown
- 2014-05-08 KR KR1020157034918A patent/KR101761049B1/ko active IP Right Grant
- 2014-05-08 BR BR112015028017A patent/BR112015028017A2/pt not_active Application Discontinuation
- 2014-05-09 UY UY0001035559A patent/UY35559A/es not_active Application Discontinuation
- 2014-05-09 AR ARP140101893A patent/AR096246A1/es unknown
- 2014-08-05 UA UAA201510960A patent/UA112618C2/uk unknown
-
2015
- 2015-11-05 PH PH12015502534A patent/PH12015502534A1/en unknown
- 2015-11-09 CL CL2015003280A patent/CL2015003280A1/es unknown
- 2015-12-04 CR CR20150639A patent/CR20150639A/es unknown
-
2016
- 2016-06-24 HK HK16107380.5A patent/HK1219278A1/zh not_active IP Right Cessation
- 2016-08-17 US US15/239,422 patent/US10017501B2/en active Active
- 2016-09-05 HK HK16110539.9A patent/HK1222646A1/zh unknown
-
2018
- 2018-06-06 US US16/001,832 patent/US20180282316A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR110405A1 (es) | Compuestos | |
| AR108130A1 (es) | Derivados de pirazolopirimidina | |
| EA201500875A1 (ru) | СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
| PE20160200A1 (es) | Inhibidores de bromodominios | |
| AR096075A2 (es) | Derivados fusionados de pirimidina para la inhibición de la actividad quinasa de tirosina | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092835A1 (es) | Compuestos de d-aminoacido para enfermedades del higado | |
| AR095339A1 (es) | Compuestos moduladores alostericos de la hemoglobina | |
| GT201200322A (es) | Derivados de carbamato de hexafluoroisoprofilo, su preparacion y su aplicacion en terapeutica | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |